Brean Murray comments on Dendreon (Nasdaq: DNDN), saying a PROVENGE panelist voiced concerns to FDA. The firm said Dr ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE